CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas

Development Program Can Support Approval, No New Studies Requested NDA Submission by CytRx Being Prepared Conference Call on April 19, 2017 at 8:30 AM EDT/ 5:30 AM PDT LOS ANGELES, April 19, 2017 -- (Healthcare Sales & Marketing Network) -- CytRx... Biopharmaceuticals, Oncology, FDA CytRx, aldoxorubicin, soft tissue sarcoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news